Loading
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Journal article
Cell Proliferation · August 5, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical mechanistic study demonstrating that MMP1 mediates the collagen-degrading capacity of hESC-derived IMRCs in cell and mouse pulmonary fibrosis models. While the work identifies MMP1 as a putative biomarker for IMRC-based IPF therapy, it does not establish clinical efficacy and represents exploratory mechanistic evidence requiring translation to human studies.
Preclinical mechanistic study with gene-edited cell model and in vivo animal experiments. A549 lung cancer cells in vitro; mice with bleomycin-induced pulmonary fibrosis in vivo. Intervention: Wild-type hESC-derived immunity-and-matrix-regulatory cells (IMRCs) and MMP1 knockout IMRCs (IMRCs-MMP1 KO). Compared with: IMRCs-MMP1 KO versus wild-type IMRCs; implicitly untreated or vehicle control in animal models.
MMP1 knockout was successfully achieved without compromising typical IMRC characteristics or immunomodulatory capacity MMP1 deficiency significantly attenuated the ability of IMRCs to degrade TGF-β1-induced collagen I deposition in A549 cells Wild-type IMRCs demonstrated superior therapeutic efficacy in ameliorating bleomycin-induced lung injury and fibrosis in mice compared with IMRCs-MMP1 KO
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work is exploratory and does not yet warrant clinical application. It suggests a mechanistic rationale for IMRC-based therapy in IPF but requires validation in human tissue systems and eventual clinical trials to establish therapeutic relevance.
Mechanistic study using gene-edited cells and animal models to establish MMP1 as a biomarker, but lacks human efficacy data and represents exploratory preclinical work rather than a clinical trial or definitive evidence.
As stated by the source record.
Quoted from the source exactly as published.
This work is exploratory and does not yet warrant clinical application. It suggests a mechanistic rationale for IMRC-based therapy in IPF but requires validation in human tissue systems and eventual clinical trials to establish therapeutic relevance.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Currently, no targeted therapy exists for idiopathic pulmonary fibrosis (IPF). The hallmark pathological feature of excessive extracellular matrix (ECM) deposition severely undermines the efficacy of mesenchymal stem cell (MSC)-based treatments. While existing MSC therapeutic strategies primarily focus on modulating inflammation in early stages, they have not yet established precise interventions addressing the core pathological mechanism-ECM dysregulation. Previous studies demonstrated the therapeutic potential of human embryonic stem cell (hESCs)-derived immunity-and-matrix-regulatory cells (IMRCs) in lung injury and fibrosis models. However, the critical biomarkers and underlying mechanisms mediating IMRCs' efficacy in IPF remain poorly understood. In this study, we generated MMP1 knockout IMRCs (IMRCs-MMP1 KO) using CRISPR-based gene editing. We then characterized whether MMP1 ablation affected key properties of IMRCs, including cell morphology, proliferation, migration, marker protein expression, transcriptomic profile, and cytokine secretion. Subsequently, the ability of IMRCs-MMP1 KO to degrade collagen was tested using in vivo and in vitro pulmonary fibrosis models. MMP1 knockout was successfully achieved and did not compromise typical IMRC characteristics or impair their immunomodulatory capacity. However, MMP1 deficiency significantly attenuated the ability of IMRCs to degrade TGF-β1-induced collagen I deposition in A549 cells. Importantly, wild-type IMRCs demonstrated superior therapeutic efficacy in ameliorating bleomycin-induced lung injury and fibrosis in mice compared with IMRCs-MMP1 KO. Furthermore, IMRCs exhibited significantly greater capability to directly degrade the pericellular collagen I and modulate fibroblasts' activation progression within fibrotic lung tissues in a MMP1-dependent manner. In summary, our data establish that MMP1 plays an essential functional role in IMRC-mediated attenuation of PF. MMP1 thus represents a key therapeutic biomarker for IMRC-based treatment. This work provides a foundation for developing stem cell therapies tailored to the pathological features of IPF, potentially enabling adaptive treatment strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.